| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc. | Director | Common Stock | 10.6K | $154K | $14.52 | Nov 4, 2025 | Direct |
| iTeos Therapeutics, Inc. | Director | Common Stock | 22.3K | $96.1K | $4.30 | May 13, 2025 | Direct |
| Denali Therapeutics Inc. | Director | Stock Option (right to buy) | 31.9K | Nov 4, 2025 | Direct | ||
| Lexeo Therapeutics, Inc. | Director | Stock Option (right to buy) | 22.9K | Jun 26, 2025 | Direct | ||
| iTeos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | May 13, 2025 | Direct | ||
| RayzeBio, Inc. | Director | Stock Option (Right to Buy) | 0 | Feb 26, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | Nov 4, 2025 | 2 | $0 | 4 | Nov 6, 2025 | Director |
| DNLI | Denali Therapeutics Inc. | Nov 4, 2025 | 0 | $0 | 3 | Nov 6, 2025 | Director |
| LXEO | Lexeo Therapeutics, Inc. | Jun 26, 2025 | 1 | $0 | 4 | Jun 30, 2025 | Director |
| ITOS | iTeos Therapeutics, Inc. | May 13, 2025 | 2 | $96.1K | 4 | May 14, 2025 | Director |
| LXEO | Lexeo Therapeutics, Inc. | Jul 5, 2024 | 1 | $0 | 4 | Jul 8, 2024 | Director |
| LXEO | Lexeo Therapeutics, Inc. | Jul 5, 2024 | 0 | $0 | 3 | Jul 8, 2024 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 11, 2024 | 1 | $0 | 4 | Jun 13, 2024 | Director |
| RYZB | RayzeBio, Inc. | Feb 26, 2024 | 1 | $0 | 4 | Feb 27, 2024 | Director |
| RYZB | RayzeBio, Inc. | Nov 1, 2023 | 1 | $0 | 4 | Nov 1, 2023 | Director |
| RYZB | RayzeBio, Inc. | Nov 1, 2023 | 0 | $0 | 3 | Nov 1, 2023 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |